The impact of mitochondrial biology on human cancers is broad because these organelles are critical regulators of metabolism, proliferation, and apoptosis. Indeed, mitochondrial aberrations are common in multiple cancer types --- not only do mitochondrial dysfunctions correlate with disease pathogenesis, but aberrant mitochondria also negatively impact upon chemotherapeutic success. Within a cell, mitochondrial homeostasis is maintained by a process referred to as mitochondrial dynamics, which is essential for mitochondrial genome integrity, efficient ATP generation, managing ROS, and the rapid distribution of mitochondrial metabolites. Mitochondrial dynamics result from the cumulative nature of two opposing forces: mitochondrial division and mitochondrial fusion. Recent published work from my group demonstrated: (1) mitochondrial division is chronically enhanced in RAS-transformed murine cells and human cancer lines harboring mutations within the MAPK pathway, (2) the mitochondrial division machinery is essential for cellular transformation, (3) targeted therapies that inhibit oncogenic MAPK signaling turn off the mitochondrial division machinery, and (4) chronic mitochondrial division is sufficient to initiate mitochondrial dysfunction and cancer cell metabolism. For decades, the presence of mtDNA mutations and mitochondrial dysfunction in cancer has been described, but the molecular mechanisms that drive these changes and their impact on cancer biology remain speculative. While others and we identified that mitochondrial division is requisite to cancer-associated mitochondrial dysfunction and is targeted by oncogenic MAPK pathway inhibitors, the molecular mechanisms linking mitochondrial division, mitochondrial dysfunction, and cancer cell survival are poorly understood. We hypothesize that oncogenic MAPK signaling induces chronic mitochondrial fragmentation, which supports mutation of the mitochondrial genome and subsequent functional heterogeneity within the mitochondrial network. This project emerged following years of effort to identify how mitochondrial division contributes to cancer biology, and we propose three complementary specific aims.
Aim 1 : Establish that chronic mitochondrial division is responsible for cancer-associated mtDNA mutations and subsequent mitochondrial dysfunction in melanocytes.
Aim 2 : Demonstrate that chronic mitochondrial division induced mtDNA mutations link mitochondrial heterogeneity, tumorigenic potential, and metabolic plasticity.
Aim 3 : Reveal the broad requirement for chronic mitochondrial division in oncogenic transformation of cells and tissues.
These aims will be achieved by using next-generation mtDNA sequencing, state-of-the-art mitochondrial function assays, and metabolomics approaches. Together, the results of this application will reveal that: (1) chronic mitochondrial division is permissive for mtDNA mutations, mitochondrial dysfunction, and tumorigenesis; and (2) proof-of- concept evidence that pharmacologically targeting chronic mitochondrial division may provide therapeutic potential to prevent and treat cancer.

Public Health Relevance

Mitochondria within cancer cells display heterogenic genomic compositions, functions, and network dynamics. However, the causes and consequences of mitochondrial heterogeneity on cancer development, prognosis, and treatment remain unknown. Therefore, it is important to investigate these pathways to understand how cancer occurs and should be treated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA206005-01
Application #
9101128
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Espey, Michael G
Project Start
2016-04-06
Project End
2021-03-31
Budget Start
2016-04-06
Budget End
2017-03-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Galluzzi, Lorenzo; Vitale, Ilio; Aaronson, Stuart A et al. (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25:486-541
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Kumar, Anil; Katz, Liora S; Schulz, Anna M et al. (2018) Activation of Nrf2 Is Required for Normal and ChREBP?-Augmented Glucose-Stimulated ?-Cell Proliferation. Diabetes 67:1561-1575
Abbate, Franco; Badal, Brateil; Mendelson, Karen et al. (2018) FBXW7 regulates a mitochondrial transcription program by modulating MITF. Pigment Cell Melanoma Res :
Serasinghe, Madhavika N; Gelles, Jesse D; Li, Kent et al. (2018) Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition. Cell Death Dis 9:29
Trotta, Andrew P; Gelles, Jesse D; Serasinghe, Madhavika N et al. (2017) Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition. J Biol Chem 292:11727-11739
Trotta, Andrew Paul; Chipuk, Jerry Edward (2017) Mitochondrial dynamics as regulators of cancer biology. Cell Mol Life Sci 74:1999-2017
Kenny, T C; Hart, P; Ragazzi, M et al. (2017) Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPRmt to promote metastasis. Oncogene 36:4393-4404
Gelles, Jesse D; Chipuk, Jerry Edward (2017) Robust high-throughput kinetic analysis of apoptosis with real-time high-content live-cell imaging. Cell Death Dis 8:e2758
Chipuk, Jerry Edward; Luna-Vargas, Mark P A (2017) The peroxisomes strike BAK: Regulation of peroxisome integrity by the Bcl-2 family. J Cell Biol 216:547-549

Showing the most recent 10 out of 17 publications